Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib vs Sorafenib in Advanced HCC
NCT02178358Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of galunisertib in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Aug 2014; status: completed.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02178358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178358.